Launching a CNS therapy starts with solid Phase 1 science. But what happens in a rigorous, procedure-intensive PK/PD study with no margin for error that includes 4,620 timed assessments, neuroendocrine sampling, and post-dose QEEG data collection?
That’s where Clinilabs shines. Download the case study for an inside look at how our Phase 1 team successfully supported the development of a novel CNS therapy by:
- Adhering to a strict, no-window assessment schedule with 3:1 staffing
- Coordinating closely with academic key opinion leaders and neurophysiological experts
- Producing validated biomarkers used to identify future CNS drug candidates
Ready to see how our CNS-focused team transforms complexity into clarity?
